The regulatory framework of biosimilars in the European Union |
| |
Authors: | Minghetti Paola Rocco Paolo Cilurzo Francesco Vecchio Lucia Del Locatelli Francesco |
| |
Affiliation: | Department of Pharmaceutical Sciences "P. Pratesi", Università degli Studi di Milano, via G. Colombo, 71-20133 Milan, Italy. paola.minghetti@unimi.it |
| |
Abstract: | In the European Union (EU), the regulatory policy for biosimilars has enabled different biosimilar products to be marketed through an abridged application, which allows the applicant to submit a reduced dossier. Nevertheless, some manufacturers of biological products that share some characteristics with copies have opted for a full application; therefore, the number and extent of clinical studies required in these cases is increased. Here, we focus on a comparison of recombinant human erythropoietin medicinal products. We analyse and discuss clinical studies submitted to the European Medicines Agency that relate to available biosimilars and biological medicinal products that are authorised with a full dossier. We also discuss the issues of interchangeability and substitution, given that the EU allows each Member State to set their own substitution policies. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|